2025 Oncology Institute
April 19, 2025 | 5:02 PM EST
- Home
- Clinical Resources Search
- PQI: Niraparib (Zejula®): Dose Modifications Based on Weight and Platelet Counts
Niraparib (Zejula®): Dose Modifications Based on Weight and Platelet Counts
About this PQI
The purpose of this PQI is to highlight key criteria for appropriate monitoring, dosing, and administration to improve the dispensing and management of patients taking niraparib.

How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQIFind Similar Resources
All Resources
PQI
PQI
PQI
PQI
PQI: Ibrutinib Dosing Optimization
Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD
Last Updated: 04/19/2025
PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management
Author: Kayla Randle, PharmD, BCOP
Last Updated: 04/19/2025
PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Author: Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO
Last Updated: 04/19/2025
PQI: Vorasidenib (Voranigo®)
Author: Andrea Gómez, PharmD, BCACP
Last Updated: 04/19/2025
PQI in Action
PQI in Action
PQI in Action
PQI in Action
PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management
Author: Scripps Health, CA | UPMC, PA
Last Updated: 04/19/2025
PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations
Author: Florida Cancer Specialists & Research Institute, FL | Mayo Clinic, MN | Texas Oncology, TX
Last Updated: 04/19/2025
PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease
Author: University of Michigan Health-Sparrow Herbert-Herman Cancer Center, MI | Texas Oncology, TX | University of North Carolina (UNC) Health, NC
Last Updated: 04/19/2025
PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma
Author: Texas Oncology, TX | Florida Cancer Specialists & Research Institute, FL | University Hospitals Cleveland Medical Center, OH
Last Updated: 04/19/2025
PQI Podcast
PQI Podcast
PQI Podcast
PQI Podcast
The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting
Author: Ginger Blackmon, PharmD | Nick Bouchard, PharmD
Last Updated: 04/19/2025
The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program
Author: Ginger Blackmon, PharmD | Salvatore Bottiglieri, PharmD, BCOP
Last Updated: 04/19/2025
The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings
Author: Ginger Blackmon, PharmD | Shana O. Ntiri, MD, MPH, FAAFP,
Last Updated: 04/19/2025
The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team
Author: Ginger Blackmon, PharmD | April Hallatt, BSN, RN, OCN
Last Updated: 04/19/2025
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit: Abemaciclib
Last Updated: 04/19/2025
Treatment Support Kit: Temozolomide
Last Updated: 04/19/2025
Treatment Support Kit: Tivozanib
Last Updated: 04/19/2025
Treatment Support Kit: Regorafenib
Last Updated: 04/19/2025
Video
Video
Video
Video
Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide
Last Updated: 04/19/2025
Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Author: Brad Kahl, MD
Last Updated: 04/19/2025
Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications
Author: Jo Ellen Rodgers, PharmD, BCPS, BCCP
Last Updated: 04/19/2025
Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)
Author: Joyce O’Shaughnessy, MD
Last Updated: 04/19/2025
PQI
PQI in Action
PQI: PARP Inhibitor Eligibility in Ovarian Cancer
Author: Martina Fraga, PharmD
Last Updated: 04/19/2025
PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices
Author: Texas Oncology | Northwest Oncology & Hematology | Simmons Cancer Institute | Swedish American | Joliet Oncology & Hematology Associates | St. Luke’s Health System
Last Updated: 04/19/2025
PQI
PQI in Action
PQI: PARP Inhibitor Eligibility in Ovarian Cancer
Author: Martina Fraga, PharmD
Last Updated: 04/19/2025
PQI in Action: Multidisciplinary Management of Advanced Ovarian Cancer Patients within Medically Integrated Pharmacy Practices
Author: Texas Oncology | Northwest Oncology & Hematology | Simmons Cancer Institute | Swedish American | Joliet Oncology & Hematology Associates | St. Luke’s Health System
Last Updated: 04/19/2025
PQI in Action
PQI Podcast
PQI Podcast
PQI Podcast
PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management
Author: Scripps Health, CA | UPMC, PA
Last Updated: 04/19/2025
The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting
Author: Ginger Blackmon, PharmD | Nick Bouchard, PharmD
Last Updated: 04/19/2025
The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program
Author: Ginger Blackmon, PharmD | Salvatore Bottiglieri, PharmD, BCOP
Last Updated: 04/19/2025
The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings
Author: Ginger Blackmon, PharmD | Shana O. Ntiri, MD, MPH, FAAFP,
Last Updated: 04/19/2025